Keith T Flaherty
Editor-in-Chief at Clinical Cancer Research
Articles
-
Jan 14, 2025 |
tandfonline.com | Dirk Schadendorf |Reinhard Dummer |Keith T Flaherty |Caroline Robert
Plain Language SummaryWhat is this summary about? This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma. What were the results?
-
Nov 2, 2024 |
insights.citeline.com | Dennis Chang |Keith T Flaherty |Uciane Scarlett
A Tale Of Two PipelinesThe Promise And Pitfalls Of IO Exuberance And How To Rethink The Approach To Cancer Innovation21 Jan 2020 • By Dennis Chang, Keith Flaherty, and Uciane ScarlettImmuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results.
-
Jun 15, 2023 |
nature.com | Peter O’Dwyer |Keith T Flaherty
-
Jun 12, 2023 |
futuremedicine.com | Keith T Flaherty
-
Feb 7, 2023 |
nature.com | Keith T Flaherty
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →